Loading…
Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values
Aim Despite high clinical disease activity, some patients with active rheumatoid arthritis (RA) have normal acute phase reactant (APR) values. This study aimed to determine the clinical outcomes of active RA patients with normal APR values. Method Of 5376 patients with RA enrolled in the Korean obse...
Saved in:
| Published in: | International journal of rheumatic diseases 2019-05, Vol.22 (5), p.852-859 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3259-5e53fb72be8087daa3bd8d17bd13635e2c4d7d6d72e9ea4af925741cf3c7cfe73 |
| container_end_page | 859 |
| container_issue | 5 |
| container_start_page | 852 |
| container_title | International journal of rheumatic diseases |
| container_volume | 22 |
| creator | Chung, Min Kyung Park, Bohyun Kim, In Je Cho, Soo‐Kyung Kim, Dam Sung, Yoon‐Kyoung Choi, Chan‐Bum Choe, Jung‐Yoon Chung, Won Tae Hong, Seung‐Jae Kim, Tae‐Hwan Koh, Eunmi Lee, Shin‐Seok Yoon, Bo Young Park, Hyesook Bae, Sang‐Cheol Lee, Jisoo |
| description | Aim
Despite high clinical disease activity, some patients with active rheumatoid arthritis (RA) have normal acute phase reactant (APR) values. This study aimed to determine the clinical outcomes of active RA patients with normal APR values.
Method
Of 5376 patients with RA enrolled in the Korean observational study network for arthritis (KORONA) registry, 400 patients with disease duration of 2.8 at baseline, biologic‐naïve, and erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP) drawn at both baseline and 2‐year follow‐up visits were identified. Patients were grouped according to baseline APR levels: normal APRs, one APR elevated, and both APRs elevated.
Results
Baseline tender and swollen joint counts, mean CDAI and Health Assessment Questionnaire‐Disability Index (HAQ‐DI) scores were significantly lower in the normal APRs group compared with APR‐elevated groups (P |
| doi_str_mv | 10.1111/1756-185X.13469 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179450083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2179450083</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3259-5e53fb72be8087daa3bd8d17bd13635e2c4d7d6d72e9ea4af925741cf3c7cfe73</originalsourceid><addsrcrecordid>eNqFkbtLBDEQh4Movms7CdjYnOax2eyWcviCAy0U7EI2meUiu5szyXr435vzzitsTJMQvvlm-A1CZ5Rc0XyuqRTlhFbi7Yryoqx30OH2Z3f7LugBOorxnZCS8lLuowNOSikZrw9RO-3c4IzusB-T8T1E7Fu80MnBkCJeujTH2iT3CTjMYex18s5iHdI8uOQ2wOBDnw3ajAnwYq5jhiFX6SHhT92NEE_QXqu7CKeb-xi93t2-TB8ms6f7x-nNbGI4E_VEgOBtI1kDFamk1Zo3trJUNjYPzgUwU1hpSysZ1KAL3dZMyIKalhtpWpD8GF2uvYvgP3LfpHoXDXSdHsCPUTEq60IQUvGMXvxB3_0YhjydYoyRsi4FJ5m6XlMm-BgDtGoRXK_Dl6JErVagViGrVeDqZwW54nzjHZse7Jb_zTwDYg0sXQdf__nUzfNsLf4G9COSeA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2220696530</pqid></control><display><type>article</type><title>Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Chung, Min Kyung ; Park, Bohyun ; Kim, In Je ; Cho, Soo‐Kyung ; Kim, Dam ; Sung, Yoon‐Kyoung ; Choi, Chan‐Bum ; Choe, Jung‐Yoon ; Chung, Won Tae ; Hong, Seung‐Jae ; Kim, Tae‐Hwan ; Koh, Eunmi ; Lee, Shin‐Seok ; Yoon, Bo Young ; Park, Hyesook ; Bae, Sang‐Cheol ; Lee, Jisoo</creator><creatorcontrib>Chung, Min Kyung ; Park, Bohyun ; Kim, In Je ; Cho, Soo‐Kyung ; Kim, Dam ; Sung, Yoon‐Kyoung ; Choi, Chan‐Bum ; Choe, Jung‐Yoon ; Chung, Won Tae ; Hong, Seung‐Jae ; Kim, Tae‐Hwan ; Koh, Eunmi ; Lee, Shin‐Seok ; Yoon, Bo Young ; Park, Hyesook ; Bae, Sang‐Cheol ; Lee, Jisoo</creatorcontrib><description>Aim
Despite high clinical disease activity, some patients with active rheumatoid arthritis (RA) have normal acute phase reactant (APR) values. This study aimed to determine the clinical outcomes of active RA patients with normal APR values.
Method
Of 5376 patients with RA enrolled in the Korean observational study network for arthritis (KORONA) registry, 400 patients with disease duration of <2 years who had Clinical Disease Activity Index (CDAI) score of >2.8 at baseline, biologic‐naïve, and erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP) drawn at both baseline and 2‐year follow‐up visits were identified. Patients were grouped according to baseline APR levels: normal APRs, one APR elevated, and both APRs elevated.
Results
Baseline tender and swollen joint counts, mean CDAI and Health Assessment Questionnaire‐Disability Index (HAQ‐DI) scores were significantly lower in the normal APRs group compared with APR‐elevated groups (P < 0.0001). At 2‐year follow‐up, mean CDAI scores, HAQ‐DI, and percentage of the patient achieving remission were not significantly different between the normal APRs group compared with the APR‐elevated groups regardless of the baseline disease activity. However, in patients with baseline CDAI moderate to high disease activity, the normal APRs group less frequently required initiation of the biologic disease‐modifying anti‐rheumatic drugs compared with the APR‐elevated groups (P = 0.044).
Conclusion
Active RA patients with normal APR values have milder disease presentation, but similar clinical outcomes to those with elevated APRs.</description><identifier>ISSN: 1756-1841</identifier><identifier>EISSN: 1756-185X</identifier><identifier>DOI: 10.1111/1756-185X.13469</identifier><identifier>PMID: 30677239</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>active ; Acute-Phase Proteins - analysis ; acute‐phase protein ; Antirheumatic Agents - adverse effects ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - blood ; Arthritis, Rheumatoid - diagnosis ; Arthritis, Rheumatoid - drug therapy ; Biological Products - adverse effects ; Biological Products - therapeutic use ; Biomarkers - blood ; Clinical outcomes ; Disability Evaluation ; Erythrocyte sedimentation rate ; Female ; Health risk assessment ; Humans ; Male ; Middle Aged ; normal ; Registries ; Remission ; Republic of Korea ; Rheumatoid arthritis ; Severity of Illness Index ; Time Factors ; Treatment Outcome</subject><ispartof>International journal of rheumatic diseases, 2019-05, Vol.22 (5), p.852-859</ispartof><rights>2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd</rights><rights>2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.</rights><rights>International Journal of Rheumatic Diseases © 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3259-5e53fb72be8087daa3bd8d17bd13635e2c4d7d6d72e9ea4af925741cf3c7cfe73</cites><orcidid>0000-0002-1585-1022 ; 0000-0002-9635-4799 ; 0000-0001-6279-7025 ; 0000-0003-0957-0395 ; 0000-0002-5286-0593 ; 0000-0002-4691-5455 ; 0000-0002-9359-6522 ; 0000-0002-8538-9662 ; 0000-0002-3689-1226 ; 0000-0002-3542-2276 ; 0000-0001-6414-9187 ; 0000-0001-6691-8939 ; 0000-0003-4493-8837 ; 0000-0002-9803-529X ; 0000-0001-6810-7355 ; 0000-0003-4658-1093</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30677239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chung, Min Kyung</creatorcontrib><creatorcontrib>Park, Bohyun</creatorcontrib><creatorcontrib>Kim, In Je</creatorcontrib><creatorcontrib>Cho, Soo‐Kyung</creatorcontrib><creatorcontrib>Kim, Dam</creatorcontrib><creatorcontrib>Sung, Yoon‐Kyoung</creatorcontrib><creatorcontrib>Choi, Chan‐Bum</creatorcontrib><creatorcontrib>Choe, Jung‐Yoon</creatorcontrib><creatorcontrib>Chung, Won Tae</creatorcontrib><creatorcontrib>Hong, Seung‐Jae</creatorcontrib><creatorcontrib>Kim, Tae‐Hwan</creatorcontrib><creatorcontrib>Koh, Eunmi</creatorcontrib><creatorcontrib>Lee, Shin‐Seok</creatorcontrib><creatorcontrib>Yoon, Bo Young</creatorcontrib><creatorcontrib>Park, Hyesook</creatorcontrib><creatorcontrib>Bae, Sang‐Cheol</creatorcontrib><creatorcontrib>Lee, Jisoo</creatorcontrib><title>Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values</title><title>International journal of rheumatic diseases</title><addtitle>Int J Rheum Dis</addtitle><description>Aim
Despite high clinical disease activity, some patients with active rheumatoid arthritis (RA) have normal acute phase reactant (APR) values. This study aimed to determine the clinical outcomes of active RA patients with normal APR values.
Method
Of 5376 patients with RA enrolled in the Korean observational study network for arthritis (KORONA) registry, 400 patients with disease duration of <2 years who had Clinical Disease Activity Index (CDAI) score of >2.8 at baseline, biologic‐naïve, and erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP) drawn at both baseline and 2‐year follow‐up visits were identified. Patients were grouped according to baseline APR levels: normal APRs, one APR elevated, and both APRs elevated.
Results
Baseline tender and swollen joint counts, mean CDAI and Health Assessment Questionnaire‐Disability Index (HAQ‐DI) scores were significantly lower in the normal APRs group compared with APR‐elevated groups (P < 0.0001). At 2‐year follow‐up, mean CDAI scores, HAQ‐DI, and percentage of the patient achieving remission were not significantly different between the normal APRs group compared with the APR‐elevated groups regardless of the baseline disease activity. However, in patients with baseline CDAI moderate to high disease activity, the normal APRs group less frequently required initiation of the biologic disease‐modifying anti‐rheumatic drugs compared with the APR‐elevated groups (P = 0.044).
Conclusion
Active RA patients with normal APR values have milder disease presentation, but similar clinical outcomes to those with elevated APRs.</description><subject>active</subject><subject>Acute-Phase Proteins - analysis</subject><subject>acute‐phase protein</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - blood</subject><subject>Arthritis, Rheumatoid - diagnosis</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biological Products - adverse effects</subject><subject>Biological Products - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Clinical outcomes</subject><subject>Disability Evaluation</subject><subject>Erythrocyte sedimentation rate</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>normal</subject><subject>Registries</subject><subject>Remission</subject><subject>Republic of Korea</subject><subject>Rheumatoid arthritis</subject><subject>Severity of Illness Index</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1756-1841</issn><issn>1756-185X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFkbtLBDEQh4Movms7CdjYnOax2eyWcviCAy0U7EI2meUiu5szyXr435vzzitsTJMQvvlm-A1CZ5Rc0XyuqRTlhFbi7Yryoqx30OH2Z3f7LugBOorxnZCS8lLuowNOSikZrw9RO-3c4IzusB-T8T1E7Fu80MnBkCJeujTH2iT3CTjMYex18s5iHdI8uOQ2wOBDnw3ajAnwYq5jhiFX6SHhT92NEE_QXqu7CKeb-xi93t2-TB8ms6f7x-nNbGI4E_VEgOBtI1kDFamk1Zo3trJUNjYPzgUwU1hpSysZ1KAL3dZMyIKalhtpWpD8GF2uvYvgP3LfpHoXDXSdHsCPUTEq60IQUvGMXvxB3_0YhjydYoyRsi4FJ5m6XlMm-BgDtGoRXK_Dl6JErVagViGrVeDqZwW54nzjHZse7Jb_zTwDYg0sXQdf__nUzfNsLf4G9COSeA</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Chung, Min Kyung</creator><creator>Park, Bohyun</creator><creator>Kim, In Je</creator><creator>Cho, Soo‐Kyung</creator><creator>Kim, Dam</creator><creator>Sung, Yoon‐Kyoung</creator><creator>Choi, Chan‐Bum</creator><creator>Choe, Jung‐Yoon</creator><creator>Chung, Won Tae</creator><creator>Hong, Seung‐Jae</creator><creator>Kim, Tae‐Hwan</creator><creator>Koh, Eunmi</creator><creator>Lee, Shin‐Seok</creator><creator>Yoon, Bo Young</creator><creator>Park, Hyesook</creator><creator>Bae, Sang‐Cheol</creator><creator>Lee, Jisoo</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1585-1022</orcidid><orcidid>https://orcid.org/0000-0002-9635-4799</orcidid><orcidid>https://orcid.org/0000-0001-6279-7025</orcidid><orcidid>https://orcid.org/0000-0003-0957-0395</orcidid><orcidid>https://orcid.org/0000-0002-5286-0593</orcidid><orcidid>https://orcid.org/0000-0002-4691-5455</orcidid><orcidid>https://orcid.org/0000-0002-9359-6522</orcidid><orcidid>https://orcid.org/0000-0002-8538-9662</orcidid><orcidid>https://orcid.org/0000-0002-3689-1226</orcidid><orcidid>https://orcid.org/0000-0002-3542-2276</orcidid><orcidid>https://orcid.org/0000-0001-6414-9187</orcidid><orcidid>https://orcid.org/0000-0001-6691-8939</orcidid><orcidid>https://orcid.org/0000-0003-4493-8837</orcidid><orcidid>https://orcid.org/0000-0002-9803-529X</orcidid><orcidid>https://orcid.org/0000-0001-6810-7355</orcidid><orcidid>https://orcid.org/0000-0003-4658-1093</orcidid></search><sort><creationdate>201905</creationdate><title>Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values</title><author>Chung, Min Kyung ; Park, Bohyun ; Kim, In Je ; Cho, Soo‐Kyung ; Kim, Dam ; Sung, Yoon‐Kyoung ; Choi, Chan‐Bum ; Choe, Jung‐Yoon ; Chung, Won Tae ; Hong, Seung‐Jae ; Kim, Tae‐Hwan ; Koh, Eunmi ; Lee, Shin‐Seok ; Yoon, Bo Young ; Park, Hyesook ; Bae, Sang‐Cheol ; Lee, Jisoo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3259-5e53fb72be8087daa3bd8d17bd13635e2c4d7d6d72e9ea4af925741cf3c7cfe73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>active</topic><topic>Acute-Phase Proteins - analysis</topic><topic>acute‐phase protein</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - blood</topic><topic>Arthritis, Rheumatoid - diagnosis</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biological Products - adverse effects</topic><topic>Biological Products - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Clinical outcomes</topic><topic>Disability Evaluation</topic><topic>Erythrocyte sedimentation rate</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>normal</topic><topic>Registries</topic><topic>Remission</topic><topic>Republic of Korea</topic><topic>Rheumatoid arthritis</topic><topic>Severity of Illness Index</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chung, Min Kyung</creatorcontrib><creatorcontrib>Park, Bohyun</creatorcontrib><creatorcontrib>Kim, In Je</creatorcontrib><creatorcontrib>Cho, Soo‐Kyung</creatorcontrib><creatorcontrib>Kim, Dam</creatorcontrib><creatorcontrib>Sung, Yoon‐Kyoung</creatorcontrib><creatorcontrib>Choi, Chan‐Bum</creatorcontrib><creatorcontrib>Choe, Jung‐Yoon</creatorcontrib><creatorcontrib>Chung, Won Tae</creatorcontrib><creatorcontrib>Hong, Seung‐Jae</creatorcontrib><creatorcontrib>Kim, Tae‐Hwan</creatorcontrib><creatorcontrib>Koh, Eunmi</creatorcontrib><creatorcontrib>Lee, Shin‐Seok</creatorcontrib><creatorcontrib>Yoon, Bo Young</creatorcontrib><creatorcontrib>Park, Hyesook</creatorcontrib><creatorcontrib>Bae, Sang‐Cheol</creatorcontrib><creatorcontrib>Lee, Jisoo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chung, Min Kyung</au><au>Park, Bohyun</au><au>Kim, In Je</au><au>Cho, Soo‐Kyung</au><au>Kim, Dam</au><au>Sung, Yoon‐Kyoung</au><au>Choi, Chan‐Bum</au><au>Choe, Jung‐Yoon</au><au>Chung, Won Tae</au><au>Hong, Seung‐Jae</au><au>Kim, Tae‐Hwan</au><au>Koh, Eunmi</au><au>Lee, Shin‐Seok</au><au>Yoon, Bo Young</au><au>Park, Hyesook</au><au>Bae, Sang‐Cheol</au><au>Lee, Jisoo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values</atitle><jtitle>International journal of rheumatic diseases</jtitle><addtitle>Int J Rheum Dis</addtitle><date>2019-05</date><risdate>2019</risdate><volume>22</volume><issue>5</issue><spage>852</spage><epage>859</epage><pages>852-859</pages><issn>1756-1841</issn><eissn>1756-185X</eissn><abstract>Aim
Despite high clinical disease activity, some patients with active rheumatoid arthritis (RA) have normal acute phase reactant (APR) values. This study aimed to determine the clinical outcomes of active RA patients with normal APR values.
Method
Of 5376 patients with RA enrolled in the Korean observational study network for arthritis (KORONA) registry, 400 patients with disease duration of <2 years who had Clinical Disease Activity Index (CDAI) score of >2.8 at baseline, biologic‐naïve, and erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP) drawn at both baseline and 2‐year follow‐up visits were identified. Patients were grouped according to baseline APR levels: normal APRs, one APR elevated, and both APRs elevated.
Results
Baseline tender and swollen joint counts, mean CDAI and Health Assessment Questionnaire‐Disability Index (HAQ‐DI) scores were significantly lower in the normal APRs group compared with APR‐elevated groups (P < 0.0001). At 2‐year follow‐up, mean CDAI scores, HAQ‐DI, and percentage of the patient achieving remission were not significantly different between the normal APRs group compared with the APR‐elevated groups regardless of the baseline disease activity. However, in patients with baseline CDAI moderate to high disease activity, the normal APRs group less frequently required initiation of the biologic disease‐modifying anti‐rheumatic drugs compared with the APR‐elevated groups (P = 0.044).
Conclusion
Active RA patients with normal APR values have milder disease presentation, but similar clinical outcomes to those with elevated APRs.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30677239</pmid><doi>10.1111/1756-185X.13469</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1585-1022</orcidid><orcidid>https://orcid.org/0000-0002-9635-4799</orcidid><orcidid>https://orcid.org/0000-0001-6279-7025</orcidid><orcidid>https://orcid.org/0000-0003-0957-0395</orcidid><orcidid>https://orcid.org/0000-0002-5286-0593</orcidid><orcidid>https://orcid.org/0000-0002-4691-5455</orcidid><orcidid>https://orcid.org/0000-0002-9359-6522</orcidid><orcidid>https://orcid.org/0000-0002-8538-9662</orcidid><orcidid>https://orcid.org/0000-0002-3689-1226</orcidid><orcidid>https://orcid.org/0000-0002-3542-2276</orcidid><orcidid>https://orcid.org/0000-0001-6414-9187</orcidid><orcidid>https://orcid.org/0000-0001-6691-8939</orcidid><orcidid>https://orcid.org/0000-0003-4493-8837</orcidid><orcidid>https://orcid.org/0000-0002-9803-529X</orcidid><orcidid>https://orcid.org/0000-0001-6810-7355</orcidid><orcidid>https://orcid.org/0000-0003-4658-1093</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-1841 |
| ispartof | International journal of rheumatic diseases, 2019-05, Vol.22 (5), p.852-859 |
| issn | 1756-1841 1756-185X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179450083 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | active Acute-Phase Proteins - analysis acute‐phase protein Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Biological Products - adverse effects Biological Products - therapeutic use Biomarkers - blood Clinical outcomes Disability Evaluation Erythrocyte sedimentation rate Female Health risk assessment Humans Male Middle Aged normal Registries Remission Republic of Korea Rheumatoid arthritis Severity of Illness Index Time Factors Treatment Outcome |
| title | Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T06%3A19%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcomes%20of%20patients%20with%20active%20rheumatoid%20arthritis%20with%20normal%20acute%20phase%20reactant%20values&rft.jtitle=International%20journal%20of%20rheumatic%20diseases&rft.au=Chung,%20Min%20Kyung&rft.date=2019-05&rft.volume=22&rft.issue=5&rft.spage=852&rft.epage=859&rft.pages=852-859&rft.issn=1756-1841&rft.eissn=1756-185X&rft_id=info:doi/10.1111/1756-185X.13469&rft_dat=%3Cproquest_cross%3E2179450083%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3259-5e53fb72be8087daa3bd8d17bd13635e2c4d7d6d72e9ea4af925741cf3c7cfe73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2220696530&rft_id=info:pmid/30677239&rfr_iscdi=true |